JMP Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $75

Moomoo NewsDec 20 17:32 ET · Ratings

Strategic Advancements and Market Potential Drive Buy Rating for Rhythm Pharmaceuticals

TipRanksDec 20 16:35 ET · Ratings

Rhythm Gets FDA Approval for Imcivree for Toddlers

Seeking AlphaDec 20 16:01 ET

FDA Expands Rhythm Pharma Obesity Drug Approval to Younger Children

WSJDec 20 15:20 ET

Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings

Seeking AlphaDec 20 15:00 ET

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

BenzingaDec 20 14:24 ET